AustralianSuper Pty Ltd Has $690,000 Stock Position in Danaher Co. (NYSE:DHR)

AustralianSuper Pty Ltd lowered its position in Danaher Co. (NYSE:DHR) by 99.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,483 shares of the conglomerate’s stock after selling 549,955 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Danaher were worth $690,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DHR. Vanguard Group Inc. boosted its stake in shares of Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares in the last quarter. Swedbank AB bought a new position in Danaher in the first quarter valued at approximately $676,545,000. TD Asset Management Inc grew its holdings in Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after acquiring an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after purchasing an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC increased its holdings in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $245.66 on Friday. Danaher Co. has a 52 week low of $188.75 and a 52 week high of $281.70. The company has a market cap of $177.44 billion, a price-to-earnings ratio of 46.88, a price-to-earnings-growth ratio of 4.45 and a beta of 0.83. The firm has a 50 day moving average of $267.38 and a 200-day moving average of $260.32. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts forecast that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is 20.61%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DHR. Barclays decreased their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Raymond James decreased their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI raised their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, Stephens reissued an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.